Due to insufficient recruitment rate, recruitmend has been terminated after inclusion of 56 patients
Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study
Sponsor study identifier
observational
56
1 country
2
Study Start
March 8, 2019
Actual (reported)Primary Completion
February 28, 2021
Actual (reported)Study Completion
February 28, 2021
Actual (reported)This is a non-interventional study to retrospectively evaluate the safety and to describe the effectiveness of cabozantinib after immunoncologic treatment with nivolumab or nivolumab plus ipilimumab in routine clinical practice. It consists of a retrospective chart review of patients who have already completed treatment with cabozantinib after nivolumab or nivolumab plus ipilimumab before inclusion.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 28, 2021
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 8, 2019
Actual (reported)October 24, 2019
Actual (reported)October 31, 2019
Actual (reported)February 28, 2021
Actual (reported)February 28, 2021
Actual (reported)Incidence of serious adverse events
Incidence of serious adverse events at least possibly related to cabozantinib treatment during and up to 30 days after the end of cabozantinib treatment
through study completion, an average of 1 year
number of dose reductions
through study completion, an average of 1 year
number of dose interruptions
through study completion, an average of 1 year
number of terminations of cabozantinib treatment due to adverse events
through study completion, an average of 1 year
ORR
through study completion, an average of 1 year
Clinical benefit rate (CBR)
through study completion, an average of 1 year
Retrospective chart review of patients who have already completed treatment with cabozantinib after nivolumab or nivolumab plus ipilimumab before inclusion.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Adults ≥ 18 years with advanced or metastatic renal cell carcinoma (all subtypes) who have completed treatment with nivolumab or nivolumab plus ipilimumab (any line of systemic therapy) directly followed by cabozantinib treatment
Uniklinik Essen
Essen, North Rhine-Westphalia, 45147, Germany
Uniklinik Münster
Münster, North Rhine-Westphalia, 48147, Germany
Salah-Eddin Al-Batran, Prof. Dr.
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
56 participants (actual enrollment reported by the registry).
First Submitted
October 24, 2019
First Posted
October 31, 2019
Study Start
March 8, 2019
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
February 28, 2021
Actual (reported)Study Completion
February 28, 2021
Actual (reported)Last Updated
December 23, 2022
Record last verified: 2022-12
No IPD will be shared
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: